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Abstract
Gadolinium based contrast agents (GBCA) have been linked
to the occurrence of nephrogenic systemic fibrosis (NSF) in
renal impaired patients. The exact interaction between the var-
ious different available formulations and occurrence of NSF is
not completely understood, but has been postulated. This as-
sociation has triggered public health advisory bodies to issue
guidelines and best practice recommendations on its use. As a
result, the reported incidence of NSF, as well as the published
use of GBCA-enhanced magnetic resonance imaging in renal
impairment, has seen a decline. Understanding of the events
that led to these recommendations can increase clinical aware-
ness and the implications of their usage. We present a review
of published literature and a brief overview of practice recom-
mendations, guidelines and manuals on contrast safety to aide
everyday imaging practice.
Teaching Points
• Low risk gadolinium based contrast agents should be the
choice in renal insufficiency.
• Higher doses have been linked to NSF development. Doses
should be as low as possible.
• Clear documentation of date, dose and type of formulation
used should be noted.
• Post-scan dialysis should be arranged as soon as possible
and feasible.
• Pre-existing inflammatory state is a risk factor; liver insuf-
ficiency is not a contraindication.
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Introduction
Gadolinium-based contrast agents (GBCA) have been linked
to the occurrence of nephrogenic systemic fibrosis (NSF) in
renal impaired patients. The majority of studies that report on
their use in the renal impaired population were published prior
to the publications that prompted the alert on NSF [1–3]. This
association has triggered public health advisory bodies to is-
sue guidelines and best practice recommendations on its use in
renal insufficiency. Since then, this has all but halted the rapid
progression and uptake of contrast-enhanced magnetic reso-
nance imaging (MRI) in this population that was seen in the
early to mid 2000s. Understanding of the events that led to
these recommendations can increase clinical awareness and
the implications of the use of GBCAs in daily imaging prac-
tice. We conducted an electronic database search [PubMed/
Medline, EMBASE] to collate the evidence in published lit-
erature on the occurance of NSF in the renal impaired.We also
carried out a forward citation and bibliographic search of iden-
tified studies. Published studies were reviewed for reported
pathophysiological and clinical manifestations, proposed di-
agnostic pathway, treatments options and reported incidence.
We also reviewed practice recommendations, guidelines and
published manuals on contrast safety.
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Background and incidence In the year 2000, 15 patients with
chronic kidney disease were identified presenting with
scleromyxoedema-like cutaneous manifestations yet having
significant clinical and histo-pathological differences; the term
nephrogenic fibrosing dermopathy was initially proposed.
These clinical findings are now recognized as characteristic
of NSF [4]. Following this, case reports of similar findings and
also significant systemic involvement found on autopsy were
reported [5, 6]. Patients with end-stage renal disease were
reported to develop symptoms as early as two to four weeks
after exposure to GBCAs for MRI [1]. Exact pathogenesis
remains unclear; however, postulation of likely early dermal
manifestation of this gadolinium toxicity is proposed [7]. A
strong association is observed in the presence of both acute
renal impairment and chronic dialysis dependent renal insuf-
ficiency and other influencing co-factors that may play a role,
such as a background inflammatory process [8, 9]. As the
evidence in published literature increased, the United States
Food and Drug Administration (FDA), followed by the Euro-
pean Medicines Agency (EMA) issued an alert on the use of
GBCAs in patients with renal insufficiency [10, 11]. Since
then, public health and practice guideline bodies have pub-
lished recommendations on its use [12–14]. A 2008 multi-
centre retrospective review reported 15 cases of NSF in a total
population of 83,121 (0.02 % incidence), all of whom re-
ceived at least one administration of a GBCA. All 15 of these
cases of NSF were found in patients who had received a
higher than standard dose, increasing the incidence to
0.17 % (15 of 8997 patients). A higher than normal dose
was described as approximately between 0.2 to 0.4 mmol
per kilogram body weight. In the entire cohort, 265 patients
were on haemodialysis, but only one of them was reported to
have developed NSF (incidence 0.4 %) [3]. Another publica-
tion retrospectively collating data from four centres set to de-
termine the benchmark incidence of NSF related to the con-
firmed use of two GBCAs [15]. They reported an overall
incidence of 0.04 % at two centres that used Gadodiamide
(32 cases in 82,260 patients—administered total dose range
1 to 9.5 mmol), as compared to the 0.02% from the previously
publish study. The other two centres that used Gadopentate
dimeglumin reported an incidence of 0.003 % (four cases in
135,347 patients) with an administered dose ranging between
2.5 and 8.5.
Clinical findings As reported in the literature, specific cuta-
neous findings on clinical examination with relevant past his-
tory of GBCA exposure trigger a differential of NSF, but re-
quire histological confirmation [16–18]. It has been postulated
that the deposition of disassociated free gadolinium causes
this fibrous connective tissue formation [5]. Patients may pres-
ent with firm, erythematous and indurated plaques of skin
associated with subcutaneous oedema. The presentation may
range from hyperpigmentation, yellow papules or plaques,
blistering or even ulceration [1, 2, 8]. Resultant manifestations
include pain, severe pruritus, paraesthesia and flexion con-
tractures that can begin on the hands or feet and extend
proximally. Cutaneous calcifications maybe noted on a plain
film radiograph and confirmed on biopsy [19]. Lesions are
frequently symmetrical, often located on the lower limbs,
followed by the forearms. Idiopathic, rapid onset, unstable
hypertension has been described prior to onset of skin le-
sions. Its systemic involvement of lungs, heart, diaphragm,
liver or kidneys can vary. The international centre for re-
search on NSF, led by Prof. Dr. S.E. Cowper, states that
approximately 5 % are reported to have a fulminant course
[20]. The Girardi Score (Fig. 1, Table 1) was proposed in
2011 based on reported clinical presentations and expert
consensus, as no single laboratory test could be used as a
gold standard to diagnose NSF. This encompassed identifi-
cation of major and minor criteria on clinical findings,
coupled with histological findings.
Pathophysiology Recent theory suggests that administration
of large amounts of GBCAs, (solely excreted via kidneys for
earlier used formulations and again mainly excreted by kid-
neys in the remainder) persist in the body and may dissociate
from their carrier ligands/chelates [16, 21, 22]. These
may then bind with readily available phosphates, carbonates
or citrates, and form insoluble molecules. Several authors
mention histological findings of increased dermal collagen
bundles, CD34+ fibroblast like cells, macrophages, mucin
and transforming growth factor beta (TGFβ) in this cohort
of patients [2, 4, 5, 16, 23–25]. Pre-existing renal disease
has been the most prevalent patient characteristic.
Although the disassociated gadolinium theory has been the
widely acknowledged trigger of NSF, questions of chelated gad-
olinium in combination with pre-existing cofactors have been
raised [26]. Cofactors such as high dose erythropoietin treat-
ment, pro-inflammatory state, high serum phosphate and calci-
um, and absence of ace inhibitor treatment, have also been
linked to the appearance of NSF [27–30]. Chelated gadolinium
such as gadodiamide and gadopentetate have been shown to
directly stimulatemacrophages andmonocytes in vitro to release
profibrotic cytokines and growth factors capable of initiating
and supporting the characteristic tissue fibrosis [23, 31–33].
Hepatic insufficiency As evidence in published literature in-
creased following the initial June 2006 alert, manufacturers of
GBCAs were ordered by the FDA to add a Bblack box
warning^ the following year [34]. This elaborated on the alert
to extend caution of GBCA use in any acute or chronic renal
insufficiency patient (GFR<30 mL/min/1.73 m2), or acute
renal insufficiency of any severity due to the hepato-renal
syndrome or in the perioperative liver transplantation period.
A 2009 systematic review of NSF in liver disease patients
found no compelling evidence to suggest liver disease in itself
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as being a risk factor for developing NSF. The authors con-
cluded that NSF developed only in the setting of pre-existing
severe renal insufficiency, irrespective of liver disease status [35].
PregnancyTo date, very little data is available regardingGBCA
administration in pregnancy. Most of the published studies are
either animal studies or patient cohorts that are understandably
historic, and have small numbers and limited follow-up periods
[36–42]. As evidence of gadolinium retention after exposure
continues to pile and taking into consideration immature foetal
renal function, recommendations are much more restrictive.
Guidelines recommend that GBCAs should only be given to
pregnant women when there is a very strong clinical indication.
Breast feeding should be stopped for at least 24 hours. One of the
more stable, macrocyclic gadolinium agents (gadoterate
meglumine, gadoteridol, or gadobutrol) should be used in the
lowest dose consistent with a diagnostic result [43].
Excess chelate The vast majority of GBCA preparations con-
tain excess chelates to reduce or ensure absence of free gado-
linium in the solution, and some studies have suggested the
possibility of excess chelate to inhibit the collagenolytic prop-
erties of matrix metalloproteinase 1. The addition of excess
chelate to non-ionic linear chelate dramatically reduces the
acute toxicity [9, 37, 43]. Table 2 summates the commonly
used GBCAs, their elimination pathway, reports of NSF and
the amount of excess chelate within the preparations.
Treatment
Thus far, no consistently successful treatment for NSF has been
proposed. Improving renal function slows or arrests NSF to
allow for gradual reversal over time, and has been described
in patients who received renal transplantation [44]. Dialysis
helps to remove the contrast agent, but it cannot reverse the
fibrotic tissue formation that has already occurred as a result of
gadolinium deposition [26, 45]. With a full 4-hour dialysis
session after administration, concentration levels comparison
to predialysis have been shown to be to cleared to 88 % at 30
mins, 93 % at 90 mins, and 97 % respectively. After a third
session, a 99.7 % clearance has been demonstrated [45].
Whether this would still be associated with development of
NSF would require long-term follow-up of these patients. Oth-
er treatments such as oral and topical steroids have been tried
with varying results [16, 46]. Extracorporeal photopheresishas
shown good results in a small case series and in three patients
who were also kidney/liver recipients [47–49]. Plasmapheresis
was also utilized with acceptable results [50, 51]. Anecdotal
evidence has been reported in the use of Cytoxan, thalidomide,
ultraviolet therapy, physical therapy including deep massage
technique, pentoxyfilline (at high doses), sodium thiosulphate,
Pathology Score Clinical Score 
0 1 2 3 4 
0 Alternave Diagnosis 
1 Alternave Diagnosis Not NSF Not NSF Inconsistent 
2 Suggesve Consistent 
3 Consistent NSF 
4 Inconsistent 
 
Fig. 1 The Girardi Score using
clinical criteria and histological
findings for diagnosis of NSF
[56]








Marked induration / Peaud’orange
Clinical findings minor
criteria
Puckering / linear banding
Superficial plaque / patch
Dermal papules
Scleral plaques (<45 years)
Histological findings Increased dermal cellularity (Score +1)
CD34+ cells with tram tracking (Score+1)
Thick & thin collagen bundles (Score+1)
Preserved elastic fibres (Score -1, if absent)
Septal involvement (Score +1)
Osseous metaplasia (Score +3)
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alefacept, and imatinib mesylate, and intravenous immuno-
globulin (also at high dose and after renal transplantation)
[17]. Not having mandatory reporting, the NSF Registry, led
by Prof. Dr. S.E. Cowper, still mentioned over 380 cases in
2013 [20]. The highest incidence in Europe has been reported
in Danish registry reports [52]. The true incidence of NSF may
likely be under-reported, but in cases of confirmed NSF, renal
transplantation should be made a priority.
Guidelines
From 2006 onwards, international agencies such as the Euro-
pean Medicines Agency (EMA), the European Society for
Urological Radiology (ESUR), the US Federal Drugs Agency
(FDA), American College of Radiology (ACR) and the UK
Royal College of Radiologists (RCR) have published alerts,
precautions and recommendations on the use of GBCAs.Mul-
tiple publications, have since been gathered to form the body
of evidence for NSF; however, the vast majority have been
linked to the earlier types of contrast agents. The incidence of
NSF has been reported to be on the decline after these recom-
mendations were implemented.
While various different formulations are available on the
market, not all have been associated with NSF. Linear GBCAs
are considered the least stable, and have been linked to most
cases of the development of NSF [3, 15]. These have often
been linked to the background of an inflammatory process
[16]. Macrocyclic GBCAs for MRI have also been developed.
A recent systematic review of MRI studies in the renal
impaired noted that the majority of included studies were pub-
lished prior to the FDA alert [53]. Half of the studies reported
use of contrast types now mentioned by the EMA as having
high incidence of NSF (Table 3).
Table 2 Gadolinium based contrast agents—elimination pathway, last reported total number of administrations, occurrences of NSF and volume of
excess chelate quantity [11]







Kidney 438 90 47 25 mmol/L
Optimark®
(Gadoversetamide)
Kidney 7 11 0.8 35 mmol/L
Magnevist®
(Gadopentetate dimeglumine)





0 8 6 1 mmol/L
Primovist®
(Gadoxetic acid disodium salt)
50 % Bile
50 % Kidney





0 0 0.05 (Not known)
Prohance®
(Gadoteridol)
Kidney 1* 2 2.6 1 mmol/L
Gadovist®
(Gadobutrol)
Kidney 1 13 12.3 2 mmo/L
Dotarem®
(Gadoteric acid)
Kidney 1** 11 22.4 0
*Case published on 5 October 2009
**9 years prior to Dotarem administration, the patient had received an unknown GBCA. Case is still under investigation
Table 3 European Medicines Agency: categorisation of GBCAs according to NSF risk, based on their thermodynamic and kinetic properties [11]
High risk
A. Linear non-ionic chelates
B. Linear non-ionic chelates
A. gadoversetamide (OptiMARK®), gadodiamide (Omniscan®)
B. gadopentetic acid (Magnevist®, Magnegita®, and Gado-MRT-ratiopharm*)
Medium risk
Linear ionic chelates
Gadofosveset (Vasovist®), gadoxetic acid (Primovist®) and gadobenic acid (MultiHance®)
Low risk
Macrocyclic chelates
Gadoteric acid (Dotarem®), gadoteridol (ProHance®) and gadobutrol (Gadovist®)
*Gadopentetic acid generics
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In December 2007, the EMA recognized that the risk of
developing NSF depends on the type of gadolinium-
containing contrast agent used, and advised that these agents
should be categorized into three groups. Following this cate-
gorization, if a GBCA is to be used in a high-risk patient, then
the low risk category agents should be used. Risk and benefit
analysis assessment and informed consent should be obtained.
Always record the name and dose of the contrast agent used in
the patient records. The use of high risk GBCAs in patients
with acute kidney injury, end-stage renal disease or stage 4
and 5 chronic kidney disease is not recommended. Caution is
advised in patients with stage 3 disease (eGFR between 30
and 59 ml/min/1.73 m2). A minimal 7-day interval should be
observed between administrations [11, 12, 43].
Conclusion
& Low risk gadolinium contrast agents as identified by the
EMA should be the choice if CE MRI is to be carried out,
but only after careful risk and benefit assessment.
Informed consent should be obtained regarding GBCA
administration. As appearance of NSF can occur from
months to years after administration, clear documentation
of date, dose and type of formulation used should be in-
cluded in case notes.[13, 54].
& Dosage should be kept to a minimum, as higher doses
have been linked to the development of NSF. A minimal
7-day interval should be observed between administra-
tions [11, 14, 43, 46]. Post scan, a full 4-hour dialysis
session should be arranged for dialysis-dependent patients
[45]. Dialysis solely for contrast filtration is not rec-
ommended due to high risk of morbidity and mortality
[11, 12].
& A pre-existing pro inflammatory state in the renal im-
paired is a high risk factor [2, 3, 16, 17, 55].
& Liver insufficiency in itself is not a contraindication; how-
ever, patients may also have coexisting renal insufficiency
and thus carry a risk of NSF [35].
& There is insufficient reported data regarding GBCA use in
the pregnant and neonate population [40–42].
& Studies exploring efficacy of stronger magnetic fields,
non-contrast or low dosage, and diagnostic test accuracy
studies would aide in clinical decision making. Continu-
ing follow-up and research will be needed on low-risk
formulations in the long term.
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